Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.

Developing therapeutic antibodies often requires multiple rounds of optimization after initial discovery. Many antibody programs face costly redesign cycles because key parameters such as affinity, developability, specificity, or manufacturability were not sufficiently addressed early in the process. These redesign cycles can significantly extend timelines, increase costs, and delay the progression of promising therapeutic candidates.

In this webinar, we will explore how integrated discovery and engineering strategies can help teams progress from initial hits to optimized lead candidates in under 12 months. Using real-world program insights, we will discuss how early developability assessment, multiparametric optimization, and platform integration can reduce downstream risk and accelerate antibody programs toward development.

Key Topics:

• Understand why many antibody discovery programs require costly redesign cycles


• Learn strategies to accelerate the transition from hit to optimized lead candidates


• Discover how early developability considerations improve downstream success


• Explore integrated discovery and engineering approaches that shorten development timelines


• Identify key factors that increase the probability of success in antibody programs